MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic dysfunction-associated steatohepatitis (MASH): Moderator Sobia Laique, MD, of the Cleveland ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Scott Isaacs, MD: ...
This article originally appeared on HCPLive®. The FDA has granted breakthrough therapy designation (BTD) for pemvidutide for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results